We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Benchmark Holdings Plc | BMK | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -3.25 | -6.77% | 44.75 | 16:35:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 44.60 | 44.60 | 46.00 | 44.75 | 48.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 26/4/2023 15:55 by belfast_child Maybe we will see BMK move into profit next quarter? Fingers crossed. |
Posted at 22/3/2023 09:50 by edwardt dnb out with a buy rating on bmk. you get the feeling this is being held back big time given the delisting position... |
Posted at 25/10/2022 08:04 by edmonda That was a positive update on a strong Q4 and BMK now sees FY22 adj EBITDA beating market expectations.Equity Development's fair value for now stays at 63p/share, vs 37p in the market, as you can read in new research note here (free access): |
Posted at 23/3/2022 20:51 by hedgehog 100 It's interesting to note BMK's strong cash position:"Cash of £50.6m and Liquidity (cash and available facility) of £61.6m as at 21 February 2022" Considering the buy-&-build strategy employed by BMK, then OTAQ, which has BMK founder Malcolm Pye as a director, could be a potential BMK takeover target. In fact, at its current share price of just 20.5p OTAQ looks a sitting duck for a BMK takeover attempt, and looks a prefect fit. Thought I think that it would have to pay at least double or treble OTAQ's current share price to succeed. "Malcolm Pye Non Executive Director Malcolm founded, and from 1999 to 2019 was Chief Executive of, Benchmark Holdings plc ("Benchmark"), the world's leading aquaculture health, nutrition and genetics business. Malcolm has over 35 years' experience in international agribusiness through his various roles at Hillsdown Holdings (then HMTF Group), and through building Benchmark from the initial start-up into a major international aquaculture technology business serving the global salmon, shrimp, tilapia and farmed fish industries. Malcolm focused Benchmark's activities on animal health, breeding and genetics, advanced nutrition and knowledge/technology delivery and led the flotation of Benchmark in 2013, maintaining a lead role in investor engagement." |
Posted at 09/3/2022 11:38 by edmonda #BMK Benchmark’s recent Q1 FY22 results highlighted strong operating trends in its three business areas and a positive outlook in key end-markets, especially farmed salmon. The group’s strong position serving the aquaculture industry should, in our view, insulate it from economic shocks resulting from the geo-political situation and thus make for attractive, safe haven investment.The company has a strong balance sheet and liquidity position following its £20m equity fundraising last year, which we consider will become a more prominent positive element in its investment case. However, Benchmark will have to refinance its NOK855m senior bond, which falls due on in July 2023. Doing so would remove something that may otherwise become an overhang as it approaches the due date. Benchmark will have to contend with significant input cost inflation and will undoubtedly see some knock-on effects from disruption to its customers’ end markets. Although the Q1 results would ordinarily have supported a modest upgrade, we have decided to maintain our current financial forecasts pending greater clarity. These forecasts support a DCF-based valuation of £583m, equivalent to 83p/share. |
Posted at 14/2/2022 12:50 by km18 ...from a while ago ...Benchmark Holdings issued a trading update earlier in the week. There is continued good momentum across all business areas, FY21 results are expected to be significantly ahead of market expectations. The Group's Adjusted EBITDA for FY21 is expected to be significantly ahead of the current market consensus which is £15.9m. This suggests that the company could even post positive EPS in FY21 for the first time in 7 years. But valuation is not particularly attractive, PS ratio of near 4 is bottom half for the Pharmaceuticals sector. The company ran at a loss for 7 years in a row between FY14 and FY20, there is no rush to buy here. But BMK is quite an interesting company and perhaps a share to monitor for now....from WealthOracleAM |
Posted at 03/2/2022 14:33 by edmonda #BMK - save the date! Benchmark Holdings plc, the aquaculture biotechnology company, will be conducting an investor webinar following publication of their Q1 results. The online presentation will be hosted by Trond Williksen, CEO, and Septima Maguire, CFO.This event will take place at 12.00pm on Tuesday 22nd February. Sign up here at the link: |
Posted at 16/12/2021 07:29 by edmonda #BMK Benchmark Holdings’ FY21 and particularly its Q4 (July to September) results confirmed the strong recovery in the business, led by its nutrition business, that had been indicated in the October pre-close trading update. An improving outlook in its key shrimp market and good conditions in the salmon and sea bass/bream sectors underpins an upgrade of our financial forecasts for FY22 and beyond.With £20m raised via a placing, Benchmark is now in a stronger position to invest in capital expansion projects ahead of the refinancing of its NOK bond, which falls due in 2023. A possible share listing in Norway next year may also provide better access to aquaculture-specific investors/capital. Taken together, these elements boost our overall valuation. We have updated our model and increased our expectations across the board to reflect the current outlook and trends as well as the placing of 33m shares at 62p/share. Our revised estimate of the fair value is now £583m, up from £550m, which is equivalent to 83p/share based on the enlarged share count. |
Posted at 30/11/2021 08:13 by tomps2 Benchmark (BMK) full year 2021 results presentation - November 2021Benchmark’s CEO, Trond Williksen and CFO, Septima Maguire present the full year results for the period ended 30th September 2021. Watch the video here: Or listen to the podcast here: |
Posted at 08/9/2021 19:17 by murdo mcsponge That's been my belief. If they have come up with either disease resistant shrimp, or a way of stimulating something akin to an immune response, I believe that would be a serious winner with a very big market. I thought that Shrimp didn't have an immune response, and I did ask Malcolm Pye about it at an AGM about 3 or 4 years ago, and he indicated that while they don't have the sort of immune system that we recognize, they do have some sort of system for fighting off infections. If BMK have something, the market should be enormous, and it's one of the main reasons BMK is the biggest holding in my Portfolio. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
